Bempedoic Acid for Lipid Management in the Indian Population: An Expert Opinion

被引：2

作者：

Hiremath, Jagdish ^{[1
]}

Mohan, J. C. ^{[2
]}

Hazra, Prakash ^{[3
]}

Sawhney, J. P. S. ^{[4
]}

Mehta, Ashwani ^{[4
]}

Shetty, Sadanand ^{[5
]}

Oomman, Abraham ^{[6
]}

Shah, Mahesh K. ^{[7
]}

Bantwal, Ganapathi ^{[8
]}

Agarwal, Rajeev ^{[9
]}

Karnik, Rajiv ^{[10
]}

Jain, Peeyush ^{[11
]}

Ray, Saumitra ^{[12
]}

Das, Sambit ^{[13
]}

Jadhao, Vibhuti ^{[14
]}

Suryawanshi, Sachin ^{[14
]}

Barkate, Hanmant ^{[14
]}

机构：

[1] Ruby Hall Clin, Cardiol, Pune, Maharashtra, India

[2] Jaipur Golden Hosp, Cardiol, Jaipur, Rajasthan, India

[3] Apollo Clin Hosp, Cardiol, Kolkata, India

[4] Sir Ganga Ram Hosp, Cardiol, New Delhi, India

[5] Sadanand Hlth Living Ctr P Ltd, Cardiol, Mumbai, India

[6] Apollo Hosp, Cardiol, Chennai, Tamil Nadu, India

[7] MKs Heart Care, Cardiol, Mumbai, India

[8] Johns Med Coll & Hosp, Endocrinol Diabet & Metab, Bengaluru, India

[9] Jaswant Rai Specialty Hosp, Cardiol, Meerut, India

[10] Karniks Cardiac Clin, Cardiol, Mumbai, India

[11] Fortis Escorts Heart Inst &Res Ctr, Cardiol, Delhi, India

[12] Woodlands Multispecial Hosp, Cardiol, Kolkata, India

[13] HiTech Med Coll & Hosp, Endocrinol, Bhubaneswar, India

[14] Glenmark Pharmaceut Ltd, Global Med Affairs, Mumbai, India

来源：

CUREUS JOURNAL OF MEDICAL SCIENCE | 2023年 / 15卷 / 02期

关键词：

india; c-reactive protein; cardiovascular disease; lipid lowering agents; bempedoic acid; DENSITY-LIPOPROTEIN-CHOLESTEROL; CARDIOVASCULAR-DISEASE; ADDING EZETIMIBE; EFFICACY; SAFETY; DYSLIPIDEMIA; GUIDELINES; REDUCTION; OUTCOMES; THERAPY;

D O I：

10.7759/cureus.35395

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Lipid-lowering is a central theme in the management of patients with atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (HeFH), with statins being currently used as the first-line lipid-lowering agent (LLAs). Bempedoic acid (BA) has been recently approved for lipid management in ASCVD/HeFH patients. This expert opinion paper brings out the essential concept to assess the current place of BA in the Indian population. Here we highlight that the majority of the patients with clinical ASCVD may not be receiving the optimal dose of statin, thereby failing to achieve their lipid targets. The addition of BA to statin results in a significant reduction in low-density lipoprotein cholesterol (LDL-C) along with substantial reductions in non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), and high-sensitivity C-reactive protein (hsCRP) levels. For patients who do not achieve LDL-C targets, BA can be an effective add-on alternative to choose among non-statin LLAs. BA is a good choice for statin-intolerant cases, especially in combination with ezetimibe. Given the lack of effect of worsening hyperglycemia or any increase in the occurrence of new-onset diabetes, BA can be used without hesitation in patients with diabetes. The small risk of hyperuricemia could be mitigated with appropriate patient selection and monitoring of serum uric acid levels in patients at high risk of hyperuricemia. We believe BA is an excellent non-statin therapy that is efficacious, well-tolerated, and cost-effective for lipid management in ASCVD, HeFH, and statin-intolerant patients in India.

引用

页数：10

共 47 条

[1] Low-density lipoprotein-cholesterol target attainment according to the 2011 and 2016 ESC/EAS dyslipidaemia guidelines in patients with a recent myocardial infarction: nationwide cohort study, 2013-17 [J].